Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
Details
Serval ID
serval:BIB_D3769B87B898
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
Journal
Breast Cancer Research and Treatment
Contributor(s)
Goldhirsch A., Coates AS., Thürlimann B., Castiglione-Gertsch M., Coates AS., Gelber RD., Goldhirsch A., Green M., Hiltbrunner A., Holmberg SB., Hossfeld DK., Láng I., Stahel R., de Stoppani M., Veronesi A., Castiglione-Gertsch M., Thürlimann B., Hiltbrunner A., Egli G., Rabaglio M., Maibach R., Marbot E., Studer R., Schärlig-Strausak M., Gelber RD., Price KN., Regan MM., Cole B., Sun Z., Zahrieh D., Gelber S., Giobbie-Hurder A., Blacher L., Celano J., Hinkle R., Isley M., Scolese T., Gusterson B., Viale G., Mallon E., Bernhard J., Hürny Ch., Gusset H., Mathys N., Cliffe B., Rudenstam CM., Wallgren A., Ottosson-Lönn S., Hultborn R., Colldahl-Jädeström G., Cahlin E., Mattsson J., Holmberg SB., Ruusvik O., Niklasson LG., Dahlin S., Karlsson G., Lindberg B., Sundbäck A., BergegArdh S., Groot O., Dahlbäck LO., Salander H., Andersson C., Heideman M., Nissborg A., Wallin A., Claes G., Ramhult T., Svensson JH., Liedberg P., Nilsson A., Havel G., Oestberg G., Persson S., Suurkla M., Matusik J., Veronesi A., Crivellari D., Monfardini S., Galligioni E., Magri MD., Buonadonna A., Massarut S., Rossi C., Candiani E., Carbone A., Volpe R., Roncadin M., Arcicasa M., Coran F., Morassut S., Goldhirsch A., Colleoni M., Martinelli G., Peruzzotti G., Orlando L., Nolè F., Torrisi R., Luini A., Orecchia R., Viale G., Peccatori F., de Braud F., Costa A., Zurrida S., Veronesi P., Sacchini V., Galimberti V., Intra M., Veronesi U., Foladore S., Foghin L., Pamich G., Bianchi C., Marino B., Murgia A., Milan V., Simoncini E., Marini G., Marpicati P., Braga M., Grigolato P., Lucini L., Lindtner J., Erzen D., Cufer T., Cervek J., Cerar O., Zakotnik B., Majdic E., Golouh R., Lamovec J., Jancar J., Vrhovec I., Kramberger M., Cortès-Funes H., Mendiola D., Gravalos C., Colomer , Mendez M., Cruz Vigo F., Miranda P., Sierra A., Martinez-Tello F., Garzon A., Alonso S., Ferrero A., Vargas C., Forbes JF., Lindsay D., Forbes JF., Bishop J., Bray S., Stewart J., Ackland S., Bonaventura A., Jackson D., Foster H., Cox S., Gourlay R., Sillar R., O'Brien P., Hamilton C., Denham J., Brew S., Collins J., Snyder R., Abdi E., Basser R., Burns I., Chipman M., Chirgwin J., Drummond R., Francis P., Green M., Gregory P., Hart S., Henderson M., Kitchen P., McLennan R., Murphy C., Neil S., Pitcher M., Richardson G., Rodger A., Schwarz M., Olver I., Robertson A., Gill P., Carter ML., Malycha P., Yeoh E., Ward G., Leong AS., Lommax-Smith J., Hoosfall D., D'Angelo R., Byrne M., van Hazel G., Dewar J., Buck M., Sterret G., Ingram D., Hastrich D., Joseph D., Cameron F., Tattersall MH., Coates AS., Niesche F., Renwick S., Donovan J., Duval P., Simes RJ., Ng A., Glenn D., North RA., Beith J., O'Connor RG., Rice M., Stevens G., Grassby J., Pendlebury S., McLeod C., Boyer M., Sullivan A., Hobbs J., Kay RG., Harvey VJ., Benjamin CS., Thompson P., Bierre A., Miller M., Hochstein B., Lethaby A., Webber J., Fey MF., Castiglione-Gertsch M., Dreher E., Schneider H., Aebi S., Buser K., Ludin J., Beck G., Haenel A., Lüthi JM., Altermatt HJ., Nandedkar M., Senn HJ., Thürlimann B., Oehlschlegel Ch., Ries G., Töpfer M., Lorenz U., Ehrsam A., Späti B., Vogel E., Cavalli F., Pagani O., Neuenschwander H., Bronz L., Sessa C., Ghielmini M., Rusca T., Rey P., Bernier J., Pedrinis E., Gyr T., Leidi L., Pastorelli G., Goldhirsch A., Caccia G., Herrmann R., Rochlitz CF., Harder JF., Köchli O., Eppenberger U., Torhorst J., Perey L., Leyvraz S., Anani P., Genton C., Gomez F., De Grandi P., Reymond P., Mirimanoff R., Gillet M., Delaloye JF., Alberto P., Bonnefoi H., Schäfer P., Krauer F., Forni M., Aapro M., Egeli R., Megevand R., Jacot-des-Combes E., Schindler A., Borisch B., Diebold S., Egli F., Forrer P., Willi A., Steiner R., Allemann J., Rüedi T., Leutenegger A., Dalla Torre U.
ISSN
1573-7217 (Electronic)
ISSN-L
0167-6806
Publication state
Published
Issued date
2009
Volume
113
Number
1
Pages
137-144
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
INTRODUCTION: International Breast Cancer Study Group (IBCSG) Trial 11-93 is the largest trial evaluating the role of the addition of chemotherapy to ovarian function suppression/ablation (OFS) and tamoxifen in premenopausal patients with endocrine-responsive early breast cancer.
METHODS: IBCSG Trial 11-93 is a randomized trial comparing four cycles of adjuvant chemotherapy (AC: doxorubicin or epirubicin, plus cyclophosphamide) added to OFS and 5 years of tamoxifen versus OFS and tamoxifen without chemotherapy in premenopausal patients with node-positive, endocrine-responsive early breast cancer. There were 174 patients randomized from May 1993 to November 1998. The trial was closed before the target accrual was reached due to low accrual rate.
RESULTS: Patients randomized tended to have lower risk node-positive disease and the median age was 45. After 10 years median follow up, there remains no difference between the two randomized treatment groups for disease-free (hazard ratio=1.02 (0.57-1.83); P=0.94) or overall survival (hazard ratio=0.97 (0.44-2.16); P=0.94).
CONCLUSION: This trial, although small, offers no evidence that AC chemotherapy provides additional disease control for premenopausal patients with lower-risk node-positive endocrine-responsive breast cancer who receive adequate adjuvant endocrine therapy. A large trial is needed to determine whether chemotherapy adds benefit to endocrine therapy for this population.
METHODS: IBCSG Trial 11-93 is a randomized trial comparing four cycles of adjuvant chemotherapy (AC: doxorubicin or epirubicin, plus cyclophosphamide) added to OFS and 5 years of tamoxifen versus OFS and tamoxifen without chemotherapy in premenopausal patients with node-positive, endocrine-responsive early breast cancer. There were 174 patients randomized from May 1993 to November 1998. The trial was closed before the target accrual was reached due to low accrual rate.
RESULTS: Patients randomized tended to have lower risk node-positive disease and the median age was 45. After 10 years median follow up, there remains no difference between the two randomized treatment groups for disease-free (hazard ratio=1.02 (0.57-1.83); P=0.94) or overall survival (hazard ratio=0.97 (0.44-2.16); P=0.94).
CONCLUSION: This trial, although small, offers no evidence that AC chemotherapy provides additional disease control for premenopausal patients with lower-risk node-positive endocrine-responsive breast cancer who receive adequate adjuvant endocrine therapy. A large trial is needed to determine whether chemotherapy adds benefit to endocrine therapy for this population.
Keywords
Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms/drug therapy, Breast Neoplasms/mortality, Chemotherapy, Adjuvant, Cyclophosphamide/administration & dosage, Doxorubicin/administration & dosage, Epirubicin/administration & dosage, Female, Follow-Up Studies, Humans, Lymph Nodes/pathology, Lymphatic Metastasis, Middle Aged, Premenopause, Receptors, Estrogen/analysis, Receptors, Progesterone/analysis, Risk Assessment, Survival Analysis, Survivors, Tamoxifen/therapeutic use
Pubmed
Web of science
Create date
26/12/2012 16:57
Last modification date
20/08/2019 15:53
Usage data
